Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: A retrospective observational study

American Journal of Kidney Diseases

Volumn 66, Issue 4, 2015, Pages 655-665

  Brunelli, Steven M ^a   Sibbel, Scott ^a   Do, Thy P ^b   Cooper, Kerry ^b   Bradbury, Brian D ^b  

^a DAVITA CLINICAL RESEARCH   (United States)

^b AMGEN INC   (United States)

Author keywords

dialysate calcium concentration; dialysate composition; End stage renal disease (ESRD); heart failure; hypocalcemia; intradialytic hypertension; metabolic bone disease; mortality; secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D; BIOLOGICAL MARKER; HEMODIALYSIS FLUID;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; DIALYSATE; FEMALE; HEALTH CARE FACILITY; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; UNITED STATES; ADVERSE EFFECTS; AGED; BLOOD; CAUSE OF DEATH; CHEMISTRY; COHORT ANALYSIS; FOLLOW UP; KIDNEY FAILURE, CHRONIC; MEDICARE; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; PROCEDURES; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STATISTICAL MODEL; STROKE; SURVIVAL; TREATMENT OUTCOME;

AGED; BIOMARKERS; CALCIUM; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMODIALYSIS SOLUTIONS; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MEDICARE; MIDDLE AGED; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84942258024     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.03.038     Document Type: Article

References (26)

1. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, and F.K. Port Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 4 1998 607 617
2. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, and G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 8 2004 2208 2218
3. R.N. Foley, P.S. Parfrey, J.D. Harnett, and et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease Am J Nephrol 16 5 1996 386 393
4. P. Houillier, M. Froissart, G. Maruani, and A. Blanchard What serum calcium can tell us and what it can't Nephrol Dial Transplant 21 1 2006 29 32
5. W.G. Goodman Vascular calcification in end-stage renal disease J Nephrol 15 suppl 6 2002 S82 S85
6. W.G. Goodman, J. Goldin, B.D. Kuizon, and et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 20 2000 1478 1483
7. A.P. Guerin, G.M. London, S.J. Marchais, and F. Metivier Arterial stiffening and vascular calcifications in end-stage renal disease Nephrol Dial Transplant 15 7 2000 1014 1021
8. L.T. Ho, and S.M. Sprague Renal osteodystrophy in chronic renal failure Semin Nephrol 22 6 2002 488 493
9. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. 2002. http://www2.kidney.org/professionals/KDOQI/guidelines-bone/Guide9.htm. Accessed April 25, 2014.
10. A. Haris, D.J. Sherrard, and G. Hercz Reversal of adynamic bone disease by lowering of dialysate calcium Kidney Int 70 5 2006 931 937
11. V. Lezaic, S. Pejanovic, S. Kostic, and et al. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study Ther Apher Dial 11 2 2007 121 130
12. G. Spasovski, S. Gelev, J. Masin-Spasovska, G. Selim, A. Sikole, and R. Vanholder Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium Bone 41 4 2007 698 703
13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
14. D. Goldsmith, E. Ritz, and A. Covic Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66 4 2004 1315 1333
15. C.B. Langman, and J.B. Cannata-Andia Calcium in chronic kidney disease: myths and realities. Introduction Clin J Am Soc Nephrol 5 suppl 1 2010 S1 S2
16. S.L. West, V.J. Swan, and S.A. Jamal Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population Clin J Am Soc Nephrol 5 suppl 1 2010 S41 S47
17. F.M. van der Sande, E.C. Cheriex, W.H. van Kuijk, and K.M. Leunissen Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients Am J Kidney Dis 32 1 1998 125 131
18. J.O. Burton, H.J. Jefferies, N.M. Selby, and C.W. McIntyre Hemodialysis-induced cardiac injury: determinants and associated outcomes Clin J Am Soc Nephrol 4 5 2009 914 920
19. T. Shoji, Y. Tsubakihara, M. Fujii, and E. Imai Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients Kidney Int 66 3 2004 1212 1220
20. B.V. Stefansson, S.M. Brunelli, C. Cabrera, and et al. Intradialytic hypotension and risk of cardiovascular disease Clin J Am Soc Nephrol 9 12 2014 2124 2132
21. G. Jean, B. Mayor, J.M. Hurot, and et al. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone Nephrol Dial Transplant 28 1 2013 176 182
22. J. Wetmore, K. Gurevich, S. Sprague, and et al. The PARADIGM trial: impact of dialysate calcium and calcium based binders [abstract] J Am Soc Nephrol 24 2013 522A
23. K. Cooper, D. Quarles, Y. Kubo, H. Tomlin, and W. Goodman Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients Nephron Clin Pract 121 3-4 2012 c124 c130
24. A. Argiles, P.G. Kerr, B. Canaud, J.L. Flavier, and C. Mion Calcium kinetics and the long-term effects of lowering dialysate calcium concentration Kidney Int 43 3 1993 630 640
25. S.H. Hou, J. Zhao, C.F. Ellman, and et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate Am J Kidney Dis 18 2 1991 217 224
26. K. Uhlig, J.S. Berns, B. Kestenbaum, and et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD) Am J Kidney Dis 55 5 2010 773 799